These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 21559815)

  • 1. Second-line chemotherapy in patients with primary unknown cancer.
    Ono M; Ando M; Yonemori K; Yamamoto H; Hirata T; Shimizu C; Tamura K; Katsumata N; Fujiwara Y
    J Cancer Res Clin Oncol; 2011 Aug; 137(8):1185-91. PubMed ID: 21559815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study.
    Pentheroudakis G; Briasoulis E; Kalofonos HP; Fountzilas G; Economopoulos T; Samelis G; Koutras A; Karina M; Xiros N; Samantas E; Bamias A; Pavlidis N;
    Acta Oncol; 2008; 47(6):1148-55. PubMed ID: 18607872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial.
    Greco FA; Rodriguez GI; Shaffer DW; Hermann R; Litchy S; Yardley DA; Burris HA; Morrissey LH; Erland JB; Hainsworth JD
    Oncologist; 2004; 9(6):644-52. PubMed ID: 15561808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial.
    Hainsworth JD; Daugaard G; Lesimple T; Hübner G; Greco FA; Stahl MJ; Büschenfelde CM; Allouache D; Penel N; Knoblauch P; Fizazi KS
    Cancer; 2015 May; 121(10):1654-61. PubMed ID: 25611313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site.
    Hainsworth JD; Spigel DR; Thompson DS; Murphy PB; Lane CM; Waterhouse DM; Naot Y; Greco FA
    Oncologist; 2009 Dec; 14(12):1189-97. PubMed ID: 19965914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line chemotherapy for carboplatin/paclitaxel-refractory ovarian cancer: are multi-agent chemotherapies of little value truly?
    Ota T; Takeshima N; Takizawa K
    Eur J Gynaecol Oncol; 2011; 32(5):471-5. PubMed ID: 22053655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical characteristics of cancer of unknown primary (CUP)--a summary of 22 cases].
    Kato S; Yasuda K; Nishino Y; Ohori H; Takahashi M; Takahashi S; Yamaura G; Ohtsuka K; Kakudo Y; Chiba N; Shimodaira H; Sakayori M; Kato S; Suzuki T; Murakawa Y; Gamoh M; Shibata H; Yoshioka T; Ishioka C
    Gan To Kagaku Ryoho; 2007 Aug; 34(8):1227-31. PubMed ID: 17687203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy with carboplatin and paclitaxel after failure of primary chemotherapy for advanced thymic carcinoma. A report of three cases and review of the literature.
    Watanabe K; Shinkai M; Goto H; Yoshikawa S; Yamaguchi N; Hara Y; Shinoda M; Moriyama Y; Rubin BK; Ishigatsubo Y; Kaneko T
    Tumori; 2013; 99(4):e172-6. PubMed ID: 24326856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taxane-sensitivity of ovarian carcinomas previously treated with paclitaxel and carboplatin.
    Ueda Y; Enomoto T; Matsuzaki S; Kobayashi E; Kimura T; Yoshino K; Fujita M; Tsutsui T; Kimura T
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1411-6. PubMed ID: 23515753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study).
    Ueda Y; Miyatake T; Nagamatsu M; Yamasaki M; Nishio Y; Yoshino K; Fujita M; Tsutsui T; Enomoto T; Kimura T
    Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):259-63. PubMed ID: 23880598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin.
    Greco FA; Erland JB; Morrissey LH; Burris HA; Hermann RC; Steis R; Thompson D; Gray J; Hainsworth JD
    Ann Oncol; 2000 Feb; 11(2):211-5. PubMed ID: 10761758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
    Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
    J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
    Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
    BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer of unknown primary site: review of consecutive cases at the National Cancer Center Hospital of Japan.
    Yakushiji S; Ando M; Yonemori K; Kohno T; Shimizu C; Katsumata N; Fujiwara Y
    Int J Clin Oncol; 2006 Dec; 11(6):421-5. PubMed ID: 17180509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irinotecan plus carboplatin for patients with carcinoma of unknown primary site.
    Yonemori K; Ando M; Yunokawa M; Hirata T; Kouno T; Shimizu C; Tamura K; Katsumata N; Hirakawa A; Matsumoto K; Yamanaka Y; Arioka H; Fujiwara Y
    Br J Cancer; 2009 Jan; 100(1):50-5. PubMed ID: 19088717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel and cisplatin in first line treatment of patients with unknown primary cancer: a multicenter study of the Anatolian Society of Medical Oncology.
    Demirci U; Coskun U; Karaca H; Dane F; Ozdemir NY; Ulas A; Baykara M; Benekli M; Ozkan M; Buyukberber S
    Asian Pac J Cancer Prev; 2014; 15(4):1581-4. PubMed ID: 24641371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taxane-based chemotherapy for patients with carcinoma of unknown primary site.
    Greco FA; Gray J; Burris HA; Erland JB; Morrissey LH; Hainsworth JD
    Cancer J; 2001; 7(3):203-12. PubMed ID: 11419028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.
    Hainsworth JD; Erland JB; Kalman LA; Schreeder MT; Greco FA
    J Clin Oncol; 1997 Jun; 15(6):2385-93. PubMed ID: 9196154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of docetaxel weekly in combination with carboplatin every 3 weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer.
    Sorbe B; Graflund M; Horvath G; Swahn M; Boman K; Bangshöj R; Lood M; Malmström H
    Int J Gynecol Cancer; 2012 Jan; 22(1):47-53. PubMed ID: 22193643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of carboplatin, irinotecan and docetaxel on a divided schedule with recombinant human granulocyte colony stimulating factor support in patients with stage IIIB or IV non-small cell lung cancer.
    Fujita A; Ohkubo T; Hoshino H; Takabatake H; Tagaki S; Sekine K
    Anticancer Drugs; 2002 Jun; 13(5):505-9. PubMed ID: 12045462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.